U.S. and China Asthma and COPD Drugs Market Is Anticipated To Witness Steady Demand by 2024

U.S. and China Asthma and COPD Drugs Market: Snapshot

The market for asthma and COPD drugs in the U.S. and China is poised to present a steady incremental opportunity in the years to come. A rise in the affected patient pool, an improved diagnosis rate for respiratory diseases, and heightened patient awareness regarding treatment options are identified as the key factors driving this market.

Get PDF Containing the Future Market Analysis of Asthma and COPD Drugs in U.S. and China Region at: http://bit.ly/2lppoPf

The U.S. and China asthma and COPD drugs market is expected to witness moderate growth in the first half of the forecast period, primarily due to the patent expiry of leading drug brands and price erosion in the market. However, by 2020, novel drugs are expected to enter the asthma and COPD drugs market, which is likely to push the market toward a positive future.

The market is slated to expand at a modest CAGR of 4.1% over the course of the forecast period, rising from a valuation of US$13.0 bn in 2015 to US$18.7 bn by 2024.

Recommendations from Global Bodies Drive Preference for Combination Drugs

Based on drug class, in 2015, combination drugs held a prominent share of over 54% in the U.S. and China asthma and COPD drugs market. The segment is slated to witness high growth during the forecast period, which is attributed to the popularity of and preference for combination drugs. The launch of triple combination therapies currently in pipeline by companies such as Chiesi Pharmaceuticals, GSK, and Circassia is also responsible for the growth of this segment.

Both in the U.S. and China, prescription is more inclined toward combination drugs as guidelines by Global Initiative for Asthma (GINA) and Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommend them as a safer option for the management of asthma and COPD.

An emerging drug class with the potential to create a prominent position in the U.S. and China asthma and COPD drugs market in the coming years is monoclonal antibodies. The launch of new products in this segment is anticipated to bolster its growth during the forecast period.

U.S. Leading Market for Asthma and COPD Drugs; China Most Lucrative

Accounting for a massive 81.4% share in the asthma and COPD drugs market by 2016, the U.S. is the clear leader and will continue its dominance through 2024. This can be primarily attributed to greater awareness among patients and higher prices of asthma and COPD drugs. New product launches, such as FDA-approved Nucala, and a rise in awareness initiatives through apps and educational programs have helped build a strong foundation for treatment in the U.S., making it a profitable country to invest in. Pipeline studies by major players for biologics as well as combination therapies is also a key trend observed over the years. Most prominent companies view the U.S. as a value market, and thus consider it an important part of their new product launch strategy.

In terms of market size, however, the asthma and COPD drugs market in the U.S. is expected to initially decline owing to lower sales triggered by a decrease in revenue from off-patent blockbuster drugs. Nevertheless, new product launches are likely to drive the market from 2021 onward.

Although China accounts for a much smaller share in the U.S. and China asthma and COPD drugs market, it has been identified to be an extremely attractive market, expanding at an impressive CAGR of 10.0% from 2016 to 2024. This is mainly driven by higher unmet medical needs in the country and a rise in the number of asthma patients. The growing incidence of COPD can be attributed to an increase in the number of smokers. A high growth rate, coupled with a low degree of competition in the market compared to the U.S., makes China an attractive investment option for makers of asthma and COPD drugs.

Read the Present Market Status of Asthma and COPD Drugs in U.S. and China Region at: http://www.transparencymarketresearch.com/us-china-asthma-copd-drugs-market.html

Key companies in the U.S. and China asthma and COPD drugs market include GlaxoSmithKline plc, F. Hoffmann-La Roche, AstraZeneca plc, Novartis AG, Boehringer Ingelheim, and Merck and Co., Inc.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

%d bloggers like this: